Isolation and Characterization of Broadly Neutralizing Human Monoclonal Antibodies to the E1 Glycoprotein of Hepatitis C Virus (cid:1)

The relative importance of humoral and cellular immunity in the prevention or clearance of hepatitis C virus (HCV) infection is poorly understood. However, there is considerable evidence that neutralizing antibodies are involved in disease control. Here we describe the detailed analysis of human monoclonal antibodies (MAbs) directed against HCV glycoprotein E1, which may have the potential to control HCV infection. We have identified two MAbs that can strongly neutralize HCV-pseudotyped particles (HCVpp) bearing the envelope glycoproteins of genotypes 1a, 1b, 4a, 5a, and 6a and less strongly neutralize HCVpp bearing the envelope glycoproteins of genotype 2a. Genotype 3a was not neutralized. The epitopes for both MAbs were mapped to the region encompassing amino acids 313 to 327. In addition, robust neutralization was also observed against cell culture-adapted viruses of genotypes 1a and 2a. Results from this study suggest that these MAbs may have the potential to prevent HCV infection.

[1]  C. G. Wu,et al.  Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma , 2007, Proceedings of the National Academy of Sciences.

[2]  P. Schürmann,et al.  Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C , 2007, Proceedings of the National Academy of Sciences.

[3]  D. Jackson,et al.  Exploiting Information Inherent in Binding Sites of Virus-Specific Antibodies: Design of An HCV Vaccine Candidate Cross-Reactive with Multiple Genotypes , 2006, Antiviral therapy.

[4]  Ralf Bartenschlager,et al.  High Density Lipoprotein Inhibits Hepatitis C Virus-neutralizing Antibodies by Stimulating Cell Entry via Activation of the Scavenger Receptor BI* , 2006, Journal of Biological Chemistry.

[5]  A. Shavinskaya,et al.  Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. El-Awady,et al.  Antibody to E1 peptide of hepatitis C virus genotype 4 inhibits virus binding and entry to HepG2 cells in vitro. , 2006, World journal of gastroenterology.

[7]  E. Galun,et al.  Preclinical Evaluation of Two Neutralizing Human Monoclonal Antibodies against Hepatitis C Virus (HCV): a Potential Treatment To Prevent HCV Reinfection in Liver Transplant Patients , 2006, Journal of Virology.

[8]  B. Bartosch,et al.  Analysis of a Highly Flexible Conformational Immunogenic Domain A in Hepatitis C Virus E2 , 2005, Journal of Virology.

[9]  S. Emerson,et al.  Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity , 2005, Hepatology.

[10]  C. Walker,et al.  Adaptive immune responses in acute and chronic hepatitis C virus infection , 2005, Nature.

[11]  Toshiaki Maruyama,et al.  Complete Replication of Hepatitis C Virus in Cell Culture , 2005, Science.

[12]  R. Bartenschlager,et al.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome , 2005, Nature Medicine.

[13]  S. Emerson,et al.  Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Karina Yusim,et al.  The Los Alamos hepatitis C sequence database , 2005, Bioinform..

[15]  G. Leroux-Roels,et al.  Immunogenicity and Tolerability of Intradermal Administration of an HCV E1-Based Vaccine Candidate in Healthy Volunteers and Patients with Resolved or Ongoing Chronic HCV Infection , 2005, Human vaccines.

[16]  G. Leroux-Roels,et al.  A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. , 2004, Vaccine.

[17]  C. Rice,et al.  Neutralizing antibody response during acute and chronic hepatitis C virus infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  T. Liang,et al.  Human Monoclonal Antibody to Hepatitis C Virus E1 Glycoprotein That Blocks Virus Attachment and Viral Infectivity , 2004, Journal of Virology.

[19]  S. Emerson,et al.  In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Cheng‐Mayer,et al.  Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  B. Bartosch,et al.  Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes , 2003, The Journal of experimental medicine.

[22]  T. Wright,et al.  Acute hepatitis C , 2001, Hepatology.

[23]  M. Manns,et al.  Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C , 2000, Nature Medicine.

[24]  M. Houghton,et al.  High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C , 1998, Hepatology.

[25]  D. Samuel,et al.  Incidence of Hepatitis C in Patients Receiving Different Preparations of Hepatitis B Immunoglobulins after Liver Transplantation , 1998, Annals of Internal Medicine.

[26]  R. Koff,et al.  Prevention of hepatitis C virus infection. , 1997, Clinics in liver disease.

[27]  M. Shapiro,et al.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[28]  R. Purcell,et al.  A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. , 1996, Virology.

[29]  K. Meyer,et al.  Peptide Immunogen Mimicry of Putative E1 Glycoprotein-Specific Epitopes in Hepatitis C Virus , 1994, Journal of virology.

[30]  M. Shapiro,et al.  Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  R. Purcell,et al.  Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses , 1994, Journal of virology.

[32]  A. Weiner,et al.  Vaccination of chimpanzees against infection by the hepatitis C virus. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R H Purcell,et al.  At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[34]  K. Matsumoto,et al.  Detection of antibodies to hepatitis C virus (HCV) structural proteins in anti-HCV-positive sera by an enzyme-linked immunosorbent assay using synthetic peptides as antigens , 1993, Journal of clinical microbiology.

[35]  B. Wahrén,et al.  Antigenic regions within the hepatitis C virus envelope 1 and non‐structural proteins: identification of an IgG3‐restricted recognition site within the envelope 1 protein , 1993, Clinical and experimental immunology.

[36]  M. Houghton,et al.  Nucleotide sequence of core and envelope genes of the hepatitis C virus genome derived directly from human healthy carriers. , 1990, Nucleic acids research.

[37]  R. Knodell,et al.  EFFICACY OF PROPHYLACTIC GAMMA-GLOBULIN IN PREVENTING NON-A, NON-B POST-TRANSFUSION HEPATITIS , 1976, The Lancet.

[38]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[39]  Willis C. Maddrey,et al.  EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. , 1999, Journal of hepatology.

[40]  G. Norkrans,et al.  Chronic hepatitis C in Sweden: genotype distribution over time in different epidemiological settings. , 1999, Scandinavian journal of infectious diseases.

[41]  H. Margolis,et al.  Strategies to prevent and control hepatitis B and C virus infections: a global perspective. , 1999, Vaccine.